Target Name: SFMBT2
NCBI ID: G57713
Other Name(s): Scm like with four mbt domains 2 | Scm-like with four MBT domains protein 2 (isoform 1) | Scm like with four mbt domains 2, transcript variant 1 | Scm like with four mbt domains 2, transcript variant 2 | SMBT2_HUMAN | OTTHUMP00000019055 | SFMBT2 variant 1 | SFMBT2 variant 2 | scm-like with 4 MBT domains protein 2 | Scm-like with four MBT domains protein 2 | Scm-related gene containing four mbt domains 2 | Scm-like with 4 MBT domains protein 2 | KIAA1617

SFMBT2: A Potential Drug Target and Biomarker

Sickle cell disease (SCD) is a genetic disorder that affects the structure of hemoglobin in red blood cells, leading to a wide range of health problems. One of the main symptoms of SCD is the presence ofSDH, sickle cell protein (HBJ3), which accumulates in the retina and damages it, leading to blindness. SFMBT2 is a gene that encodes a protein known as sickle cell protein (HBJ3), which is a key protein in the development and maintenance of sickle cells.

The search for new treatments for SCD has led to the investigation of SFMBT2 as a potential drug target and biomarker. SFMBT2 has been shown to be highly expressed in the retina and is involved in the development and progression of SCD.

Drug Target

SFMBT2 has been identified as a potential drug target due to its involvement in the development and progression of SCD. It has been shown to be highly expressed in the retina and has been linked to the development of blindness in SCD patients.

One of the main drug targets for SCD is the inhibition of the activity of the gene that encodes SFMBT2. This can be achieved through the use of small molecules, such as inhibitors, or through the use of antibodies to target the protein itself.

Biomarker

SFMBT2 has also been identified as a potential biomarker for SCD. The level of SFMBT2 in the retina can be used as a marker for the severity of SCD. This is because the level of SFMBT2 is higher in individuals with SCD, and lower in individuals without SCD.

The detection of low SFMBT2 levels in the retina could be an indication that an SCD patient may benefit from treatment, such as drug therapy or gene therapy.

Conclusion

SFMBT2 is a gene that has been shown to be involved in the development and progression of SCD. As a potential drug target and biomarker, SFMBT2 is an attractive target for the development of new treatments for SCD. Further research is needed to fully understand the role of SFMBT2 in SCD and to develop effective treatments.

Protein Name: Scm Like With Four Mbt Domains 2

Functions: Transcriptional repressor of HOXB13 gene

More Common Targets

SFN | SFPQ | SFR1 | SFRP1 | SFRP2 | SFRP4 | SFRP5 | SFSWAP | SFT2D1 | SFT2D2 | SFT2D3 | SFTA1P | SFTA2 | SFTA3 | SFTPA1 | SFTPA2 | SFTPB | SFTPC | SFTPD | SFXN1 | SFXN2 | SFXN3 | SFXN4 | SFXN5 | SGCA | SGCB | SGCD | SGCE | SGCG | SGCZ | SGF29 | SGIP1 | SGK1 | SGK2 | SGK3 | SGMS1 | SGMS1-AS1 | SGMS2 | SGO1 | SGO1-AS1 | SGO2 | SGPL1 | SGPP1 | SGPP2 | SGSH | SGSM1 | SGSM2 | SGSM3 | SGTA | SGTB | SH2B1 | SH2B2 | SH2B3 | SH2D1A | SH2D1B | SH2D2A | SH2D3A | SH2D3C | SH2D4A | SH2D4B | SH2D5 | SH2D6 | SH2D7 | SH3 domain-binding protein 1 | SH3BGR | SH3BGRL | SH3BGRL2 | SH3BGRL3 | SH3BP1 | SH3BP2 | SH3BP4 | SH3BP5 | SH3BP5-AS1 | SH3BP5L | SH3D19 | SH3D21 | SH3GL1 | SH3GL1P1 | SH3GL1P2 | SH3GL1P3 | SH3GL2 | SH3GL3 | SH3GLB1 | SH3GLB2 | SH3KBP1 | SH3PXD2A | SH3PXD2A-AS1 | SH3PXD2B | SH3RF1 | SH3RF2 | SH3RF3 | SH3RF3-AS1 | SH3TC1 | SH3TC2 | SH3TC2-DT | SH3YL1 | SHANK1 | SHANK2 | SHANK2-AS1 | SHANK2-AS3